Brian C Stephenson sold $282k of BBIO
CFO and Treasurer at BridgeBio Pharma, Inc.. 8,500 shares at an average of $33.19, traded Feb 25, 2025, filed Feb 27, 2025.
Score components
- +22RoleCFO
- +14Trade size$282k at market
- 0Share of holdings soldSold 7.7% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-029262, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 25, 2025 | MOption exercise Common Stock10b5-1 | +8,500 | $17.00 | $145k | 110,964 | Feb 27, 2025 |
| Feb 25, 2025 | SOpen-market sale Common Stock10b5-1 | -8,400 | $33.18 | $279k | 102,564 | Feb 27, 2025 |
| Feb 25, 2025 | SOpen-market sale Common Stock10b5-1 | -100 | $34.18 | $3,418 | 102,464 | Feb 27, 2025 |
| Feb 25, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -8,500 | $0.00 | $0 | 440,170 | Feb 27, 2025 |
Related signals
Other insiders at BridgeBio Pharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 26Weak | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $691k 10,000 shares | -2% | |
| 13Weak | BridgeBio Pharma, Inc. | Hannah Valantine director | $342k 5,004 shares | -35% | |
| 33Weak | BridgeBio Pharma, Inc. | Jennifer E. Cook director | $2.8M 39,363 shares | -372% | |
| 40Moderate | BridgeBio Pharma, Inc. | Jennifer E. Cook director | $6.0M 90,240 shares | -93% | |
| 43Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $5.4M 80,000 shares | -14% | |
| 45Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $1.8M 26,103 shares | -10% | |
| 25Weak | BridgeBio Pharma, Inc. | Randal W. Scott director | $671k 10,000 shares | -46% | |
| 40Moderate | BridgeBio Pharma, Inc. | Thomas Trimarchi President and CFO | $888k 13,651 shares | -4% | |
| 50Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $5.4M 80,000 shares | -13% | |
| 14Weak | BridgeBio Pharma, Inc. | Maricel Apuli Chief Accounting Officer | $143k 2,000 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.